Programmed death 1 immune checkpoint inhibitors.

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Programmed death 1 (PD-1) is an immune checkpoint protein that regulates T cell activity and maintains self-tolerance.
• Cancer cells exploit immune checkpoints, like PD-1, to evade the immune system.
• Immune checkpoint inhibitors (ICIs) are a novel immunotherapy class designed to reinvigorate anti-tumor immune responses.

Purpose of the Study:

• To review the role of PD-1 in cancer immune evasion.
• To discuss the current landscape of PD-1 inhibitors in clinical use and investigation.
• To highlight the critical need for biomarkers to predict response to PD-1 inhibitors.

Main Methods:

• Literature review of PD-1 pathway, cancer immunology, and immunotherapy clinical trials.
• Analysis of FDA-approved PD-1 inhibitors and their current indications.
• Discussion of ongoing research and future directions for PD-1 inhibitor therapy.

Main Results:

• PD-1 inhibitors, including nivolumab and pembrolizumab, have shown efficacy in various malignancies.
• Current FDA approvals for PD-1 inhibitors are limited to melanoma and non-small cell lung cancer (NSCLC).
• Several other PD-1 inhibitors are under investigation for broader applications.

Conclusions:

• PD-1 inhibitors represent a significant advancement in cancer immunotherapy.
• Biomarker identification is essential for optimizing the clinical utility of PD-1 inhibitors.
• Future research should focus on combination therapies, expanded indications, and biomarker refinement.